Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03425539 · ClinicalTrials.gov registry record · Phase 3
Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease
A Phase 3 study, sponsored by Idorsia Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 118
- Enrollment target
NCT03425539 is a Phase 3 study that has completed, run by Idorsia Pharmaceuticals. The registered enrollment target is 118 participants.
The verdict
NCT03425539, a Phase 3 study, has completed, sponsored by Idorsia Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 118 participants
- Enrollment target
Study Summary
This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.
Interventions
- DRUG Placebo
- DRUG Lucerastat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 118 participants |
| Start Date | 2018-06-21 |
| Est. Completion | 2021-09-02 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03425539
The ClinicalTrials.gov registry entry for NCT03425539 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 118 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Idorsia Pharmaceuticals, which has 34 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03425539 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03425539 about?
NCT03425539 is a clinical study titled "Efficacy and Safety of Lucerastat Oral Monotherapy in Adult Subjects With Fabry Disease". This study aimed to determine the efficacy and safety of lucerastat oral monotherapy in adult subjects with Fabry disease.
What is the current status of trial NCT03425539?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 118 participants. The study started on 2018-06-21. Estimated completion is 2021-09-02.
What interventions are being tested in trial NCT03425539?
The interventions under investigation include: Placebo (DRUG), Lucerastat (DRUG).
Who is sponsoring clinical trial NCT03425539?
This trial is sponsored by Idorsia Pharmaceuticals, which has 34 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.